A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Stopped early · Phase 2

Conditions studied: Osteoarthritis

In brief

The purpose of this study is to test MK0822 on disease activity in patients with osteoarthritis in the knee. Disease modifying activity of MK0822 will be assessed by measurements of knee cartilage using Magnetic Resonance Imaging (MRI) of the knee. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Key facts

Study ID

NCT00397683

Run by

Merck Sharp & Dohme LLC

People needed

2

Starts

2006-10-01

Expected to finish

2007-04-01

Last updated by the study team

2015-11-02

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with symptomatic knee osteoarthritis for at least 6 months based on clinical and radiographic criteria
• Patients should be in general good health and must have a certain level of knee pain or be taking pain medicines on most days
• Specific radiographic (X-ray) and MRI features must also be satisfied

You may not qualify if…

• Non-osteoarthritic causes of knee pain
• Ineligibility to undergo MRI of the knee due to patient tolerability or safety reasons
• Previous septic arthritis, tibial osteotomy or knee replacement in both knees
• Acute injury of knee ligaments or meniscus in past 2 years
• Knee arthroscopy in past 12 months
• Anticipated arthroscopy or surgery in next 18 months
• Use of intra-articular injections of hyaluronan (e.g. Hyalgan (TM), Synvisc (TM), Orthovisc (TM)) in past 6 months, or injections of glucocorticoids (e.g. Kenalog (TM), Aristospan (TM), Depo-Medrol (TM)) in past 3 months or anticipated knee injections during the study
• Glucosamine or chondroitin sulfate are allowable if they are at a stable dose for past 3 months and will continue at that dose during the study
• Other exclusion criteria apply-Please ask the study doctor for details

Where it is running

• Call for Information — Palm Desert, California, United States
• Call for Information — Pomona, California, United States
• Call for Information — Torrance, California, United States
• Call for Information — Upland, California, United States
• Call for Information — Coral Gables, Florida, United States
• Call for Information — Hialeah, Florida, United States
• Call for Information — South Miami, Florida, United States
• Call for Information — Rochester, New York, United States
• Call for Information — Rochester, New York, United States
• Call for Information — Rochester, New York, United States
• Call for Information — Norristown, Pennsylvania, United States
• Call for Information — Perkasie, Pennsylvania, United States
• Merck Sharp & Dohme (I.A.) Corp. — Santiago, Chile
• Frosst Laboratories Inc. — Bogota, Cundinamarca, Colombia
• Merck Sharp & Dohme De Mexico, S.A. De C.V. — México, D.f., Mexico
• MSD Polska Sp. z o.o. Dzial Medyczny — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.